February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
1 citations
,
October 2021 in “Deleted Journal” Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
5 citations
,
July 2024 in “Pediatric Dermatology” Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.
7 citations
,
January 2019 in “Dermatology Online Journal” Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
December 2025 in “Pediatric Dermatology” Trametinib can cause skin issues, but they can often be managed without stopping the drug.
May 2025 in “Journal of Nanobiotechnology” The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
November 2025 in “Archives of Dermatological Research” Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.
March 2026 in “Biomedicines” New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
March 2025 in “Meditsinskiy sovet = Medical Council” Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.